Nature Communications (Jan 2020)
Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity
- Mariya B. Shapiro,
- Tracy Cheever,
- Delphine C. Malherbe,
- Shilpi Pandey,
- Jason Reed,
- Eun Sung Yang,
- Keyun Wang,
- Amarendra Pegu,
- Xuejun Chen,
- Don Siess,
- David Burke,
- Heidi Henderson,
- Rebecca Lewinsohn,
- Miranda Fischer,
- Jeffrey J. Stanton,
- Michael K. Axthelm,
- Christoph Kahl,
- Byung Park,
- Anne D. Lewis,
- Jonah B. Sacha,
- John R. Mascola,
- Ann J. Hessell,
- Nancy L. Haigwood
Affiliations
- Mariya B. Shapiro
- Department of Molecular Microbiology and Immunology, Oregon Health & Science University
- Tracy Cheever
- Division of Pathobiology & Immunology, Oregon National Primate Research Center, Oregon Health & Science University
- Delphine C. Malherbe
- Division of Pathobiology & Immunology, Oregon National Primate Research Center, Oregon Health & Science University
- Shilpi Pandey
- Division of Pathobiology & Immunology, Oregon National Primate Research Center, Oregon Health & Science University
- Jason Reed
- Vaccine & Gene Therapy Institute, Oregon Health & Science University
- Eun Sung Yang
- Vaccine Research Center, NIAID/NIH
- Keyun Wang
- Vaccine Research Center, NIAID/NIH
- Amarendra Pegu
- Vaccine Research Center, NIAID/NIH
- Xuejun Chen
- Vaccine Research Center, NIAID/NIH
- Don Siess
- Molecular Virology Core, Oregon National Primate Research Center, Oregon Health & Science University
- David Burke
- Molecular Virology Core, Oregon National Primate Research Center, Oregon Health & Science University
- Heidi Henderson
- Division of Pathobiology & Immunology, Oregon National Primate Research Center, Oregon Health & Science University
- Rebecca Lewinsohn
- Division of Pathobiology & Immunology, Oregon National Primate Research Center, Oregon Health & Science University
- Miranda Fischer
- Division of Pathobiology & Immunology, Oregon National Primate Research Center, Oregon Health & Science University
- Jeffrey J. Stanton
- Division of Comparative Medicine, Oregon National Primate Research Center, Oregon Health & Science University
- Michael K. Axthelm
- Division of Pathobiology & Immunology, Oregon National Primate Research Center, Oregon Health & Science University
- Christoph Kahl
- Molecular Virology Core, Oregon National Primate Research Center, Oregon Health & Science University
- Byung Park
- Biostatistics & Bioinformatics Core, Oregon National Primate Research Center, Oregon Health & Science University
- Anne D. Lewis
- Division of Comparative Medicine, Oregon National Primate Research Center, Oregon Health & Science University
- Jonah B. Sacha
- Department of Molecular Microbiology and Immunology, Oregon Health & Science University
- John R. Mascola
- Vaccine Research Center, NIAID/NIH
- Ann J. Hessell
- Division of Pathobiology & Immunology, Oregon National Primate Research Center, Oregon Health & Science University
- Nancy L. Haigwood
- Department of Molecular Microbiology and Immunology, Oregon Health & Science University
- DOI
- https://doi.org/10.1038/s41467-019-13972-y
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 13
Abstract
Broadly neutralizing antibodies (bNAbs) are being evaluated for HIV post-exposure prophylaxis (PEP) in the setting of vertical transmission. Here, using a macaque model of perinatal SHIV infection, the authors show that PEP for infant macaques within 30–48 h of SHIV exposure is highly effective using either bNAbs or ART.
